The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

The US FDA has approved depemokimab as an add-on maintenance therapy for individuals aged 12 years or older with severe asthma, according to a press release from manufacturer GlaxoSmithKline.

We’ve launched a first-of-its-kind app to help you find out where your generic drugs come from and see the track records of ...

For many, these price reductions may represent a critical step in improving access to essential medications, especially as ...

Several common drugs will be cheaper next year under Medicare, from weight-loss drug Ozempic to breast-cancer medication ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review. The Medicines and Healthcare products ...

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for ...

Medicare beneficiaries will see major pricing shifts as federal negotiations reshape how costly prescription drugs are paid ...